Key Stats for Iovance Biotherapeutics Stock
- Price change for Iovance Biotherapeutics stock In last 6 months: 211%
- $IOVA Stock Price as of Aug. 20: $9
- 52-Week High: $9
- $IOVA Stock Price Target: $10
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Iovance Biotherapeutics (IOVA) stock has been on a tear, and UBS just raised its price target to $7.00 from $4.00 while keeping a Neutral rating.
The move comes after Iovance posted a Q2 that beat expectations across the board. Total revenue came in at $99.3 million, well above the $87.1 million analysts were expecting, marking a 66% jump from a year ago and a 39% increase from Q1.
The star of the quarter was Amtagvi, Iovance’s cancer therapy, which brought in $91 million versus a consensus estimate of $80 million. That’s a 52% jump from the prior quarter.
Management credited the growth to stronger demand driven by marketing efforts, physician education, and better performance from authorized treatment centers.
Proleukin, the company’s other product, added $9 million in revenue, just ahead of the roughly $8 million analysts expected.
Profitability also improved sharply. Gross margin jumped to 56% in Q2, up from 41% in Q1, thanks to manufacturing efficiency gains and cost savings.
UBS expects that trend to continue, projecting gross margin could reach 70% over the next two years. Adjusted loss per share came in at $0.11, narrower than the $0.13 loss analysts had forecast.
Looking ahead, UBS believes management will likely raise its full-year 2026 revenue guidance above the current range of $350 million to $370 million, based on strong near-term visibility into patient enrollment and treatment activity.
Iovance Biotherapeutics stock has climbed more than 100% since that Q2 report, and shares are now trading at $8.99, just a hair below the 52-week high. Year to date, the stock has returned an impressive 257%.
See analysts’ growth forecasts and price targets for Iovance Biotherapeutics stock (It’s free) >>>
What the Market Is Telling Us About Iovance Biotherapeutics Stock
Iovance Biotherapeutics stock’s huge run this year shows investors are increasingly convinced Amtagvi has real staying power, not just a one-quarter pop.
Still, UBS kept its rating at Neutral rather than upgrading to a buy, suggesting caution despite the raised price target. Part of that caution ties to valuation, since the stock currently appears overvalued relative to its fair value estimate.
UBS also flagged a few risks worth watching. These include potential logistical challenges as more authorized treatment centers come online, along with competitive pressure from Replimune’s Tudrigev, which could compete with Amtagvi in second-line and later melanoma treatment.
Even so, six analysts have recently revised their earnings estimates higher for the upcoming period, a sign that Wall Street sentiment is generally trending positive.
For now, Iovance Biotherapeutics stock’s massive year-to-date gain reflects genuine excitement about the company’s growth trajectory, even as some analysts stay measured about how much further the rally can run given how far the stock has already come.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Iovance Biotherapeutics Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
